Flare Therapeutics

Flare Therapeutics is a clinical-stage biotechnology company dedicated to drugging transcription factors — a previously elusive but scientifically validated class of drug targets central to cancer and other diseases. Founded in 2021 and based in Cambridge, Massachusetts, Flare has built a proprietary chemistry and proteomics engine that enables ligand discovery directly from cells, bypassing the traditional barriers that have made transcription factors so difficult to target. The company's novel switch site approach identifies allosteric pockets on transcription factors that can be modulated with small molecules, giving researchers a new handle on gene regulatory machinery. Flare's pipeline is focused on precision oncology, with lead programs targeting PPARG in urothelial cancer and prostate cancer, as well as a strategic discovery collaboration with Roche to address additional transcription factor targets. The company was launched with $82 million in Series A financing in May 2021 and has since advanced multiple programs into clinical development.